title: Sunitinib induced nephrotic syndrome and thrombotic microangiopathy.
abstract: Sunitinib is an oral, multitargeted receptor tyrosine kinase inhibitor of targets such as vascular endothelial growth factor and platelet derived growth factor receptor. It is used for the treatment of metastatic renal cell carcinoma (RCC). Use of sunitinib has been associated with renal dysfunction and nephrotic syndrome. However, simultaneous occurrence of nephrotic syndrome and renal dysfunction in a patient treated with sunitinib is rare. We report a case of metastatic RCC treated with sunitinib for 22 months who presented with nephrotic syndrome and renal dysfunction. Renal biopsy was diagnostic of thrombotic microangiopathy with diffuse effacement of podocytic foot process.
authors.affiliation: Department of Nephrology, Manipal Hospital, Bangalore, India.
authors.forename: P K
authors.initials: PK
authors.lastname: Jha
authors.forename: M
authors.initials: M
authors.lastname: Vankalakunti
authors.forename: V
authors.initials: V
authors.lastname: Siddini
authors.forename: R
authors.initials: R
authors.lastname: Bonu
authors.forename: G K
authors.initials: GK
authors.lastname: Prakash
authors.forename: K
authors.initials: K
authors.lastname: Babu
authors.forename: H S
authors.initials: HS
authors.lastname: Ballal
keywords: Nephrotic syndrome; receptor tyrosine kinase inhibitor; sunitinib; thrombotic microangiopathy